Skip to content

Avanos Medical AVNS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Pacira BioSciences, Inc. logo
Pacira BioSciences, Inc.PCRX
$1.07B+4.9%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$621.74M+4.8%
IAR
Integra LifeSciencesIART
$1.34B+1.3%
AMN Healthcare logo
AMN HealthcareAMN
$568.06M+5.6%
Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%

Other financials

Income statement

See full
Revenue$182.2M+8.8%
Gross profit$94.2M+4.9%
Operating income$8.9M-13.6%
Net income$5.1M-22.7%
EPS (diluted)$0.11-21.4%

Balance sheet

See full
Cash & equivalents$65.6M-32.4%
Total debt$138.4M-1.8%
Total equity$782.1M-6.8%
Total assets$1.1B-5.2%

Cash flow

See full
Operating cash flow-$12.3M-148%
CapEx$4.3M-35.8%
Free cash flow-$16.6M-187%

Valuation

See full
Market cap$1.17B-1.2%
Enterprise value$1.24B+3.0%
P/S1.6×-0.1×

Profitability

See full
Gross margin50%-4.6pp
Operating margin-9.1%-4.2pp
Net margin-10.4%-4.7pp
FCF margin1.6%-14.9pp

Returns & leverage

See full
Return on equity-9.2%-3.9pp
Debt / equity0.2×0.0×
Current ratio2.5×-0.1×

Where this comes from

Reported directly by Avanos Medical in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avanos Medical's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Avanos Medical's additional paid-in capital?
Avanos Medical (AVNS) reported additional paid-in capital of $1.7B in Q1 2026.
How has Avanos Medical's additional paid-in capital changed year-over-year?
Avanos Medical's additional paid-in capital increased by 0.8% year-over-year, from $1.68B to $1.7B.
What is the long-term trend for Avanos Medical's additional paid-in capital?
Over 5 years (2020 to 2025), Avanos Medical's additional paid-in capital has grown at a 1.0% compound annual growth rate (CAGR), from $1.61B to $1.69B.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.